Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Francois-Emery Cotte"'
The chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (ide-cel) is approved for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM) who have already received an immunomodulatory agent, a proteasome inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a3cc891384daad2680576aa190484be
Autor:
Valentine Grumberg, Christos Chouaïd, Anne-Françoise Gaudin, Christophe Le Tourneau, Aurélien Marabelle, Isabelle Bongiovanni-Delarozière, François-Emery Cotté, Isabelle Borget
Publikováno v:
JCO Global Oncology, Vol , Iss 9 (2023)
PURPOSEIn 2020, the French National Authority for Health (Haute Autorité de Santé) published a methodologic guide called organizational impact (OI) cartography to define and structure assessment of the OI of health technologies. As immunotherapies
Externí odkaz:
https://doaj.org/article/59e0d1489d4f43e8bdb2660661d4727d
Autor:
Jean-Baptiste Assié, Christos Chouaïd, Hilario Nunes, Dorothée Reynaud, Anne-Françoise Gaudin, Valentine Grumberg, Ronan Jolivel, Baptiste Jouaneton, François-Emery Cotté, Boris Duchemann
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC) have pre-existing interstitial lung disease (ILD). These patients are usually excluded from immunotherapy clinical trials. Consequently, knowledge on outcomes followi
Externí odkaz:
https://doaj.org/article/aaeb77ceaeb54391980a9b65f9f243ac
Autor:
Bruno Bregman, Siguroli Teitsson, Isabella Orsini, François-Emery Cotté, Adenike Amadi, Andriy Moshyk, Stéphane Roze, Anne-Françoise Gaudin
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 6, Pp 1331-1343 (2020)
Abstract Introduction The aim of the current study is to estimate the cost-effectiveness of adjuvant treatment with nivolumab relative to clinically relevant comparators in adult patients with melanoma with lymph node involvement or metastatic diseas
Externí odkaz:
https://doaj.org/article/3ca1836a69d2470da85f2918fa699c76
Autor:
Ophélie Wilczynski, Anthony Boisbouvier, Lise Radoszycki, François-Emery Cotté, Anne-Françoise Gaudin, Hervé Lemasson
Publikováno v:
Journal of Medical Internet Research, Vol 24, Iss 1, p e25792 (2022)
BackgroundNew cancer treatments, such as immune checkpoint inhibitors (ICIs), can improve survival and health-related quality of life (HRQoL) in patients with cancer. Although long-term monitoring of HRQoL has been shown to improve survival, integrat
Externí odkaz:
https://doaj.org/article/e56d312341ea4a7c866d07586553988b
Autor:
Jean-Baptiste Assié, Romain Corre, Matteo Giaj Levra, Christophe Yannick Calvet, Anne-Françoise Gaudin, Valentine Grumberg, Baptiste Jouaneton, François-Emery Cotté, Christos Chouaïd
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Objective: To describe long-term outcomes of patients treated with nivolumab for advanced non-small cell lung cancer (aNSCLC) in everyday clinical practice in France, with a focus on patients aged ⩾80 years, patients with renal impairment and patie
Externí odkaz:
https://doaj.org/article/54cab800c9de419a8b9e70d8954776a5
Autor:
Arnaud Scherpereel, Isabelle Durand-Zaleski, François-Emery Cotté, Jérôme Fernandes, Didier Debieuvre, Cécile Blein, Anne-Françoise Gaudin, Charlène Tournier, Alexandre Vainchtock, Pierre Chauvin, Pierre-Jean Souquet, Virginie Westeel, Christos Chouaïd
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)
Abstract Background Territorial differences in the access to innovative anticancer drugs have been reported from many countries. The objectives of this study were to evaluate access to innovative treatments for metastatic lung cancer in France, and t
Externí odkaz:
https://doaj.org/article/ad3734f99b804fe788808c1c80bb3664
Autor:
Fabrice Barlesi, Adrien Dixmier, Didier Debieuvre, Christophe Raspaud, Jean-Bernard Auliac, Nicolas Benoit, Pierre Bombaron, Denis Moro-Sibilot, Clarisse Audigier-Valette, Bernard Asselain, Thomas Egenod, Audrey Rabeau, Jérôme Fayette, Myriam Locatelli Sanchez, Jean-Luc Labourey, Virginie Westeel, Pauline Lamoureux, François-Emery Cotte, Victoria Allan, Melinda Daumont, Juliette Dumanoir, Dorothée Reynaud, Christophe Yannick Calvet, Nicolas Ozan, Maurice Pérol
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
EVIDENS is an ongoing, prospective, non-interventional study evaluating the effectiveness and safety of nivolumab in lung cancer patients in France (ClinicalTrials.gov NCT03382496). Adults with a pathologically confirmed diagnosis of lung cancer and
Externí odkaz:
https://doaj.org/article/213acd05a7a34a719db64a6b6903acd4
Autor:
Christos Chouaïd, Didier Debieuvre, Isabelle Durand-Zaleski, Jérôme Fernandes, Arnaud Scherpereel, Virginie Westeel, Cécile Blein, Anne-Françoise Gaudin, Nicolas Ozan, Soline Leblanc, Alexandre Vainchtock, Pierre Chauvin, François-Emery Cotté, Pierre-Jean Souquet
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0182798 (2017)
The French healthcare system is a universal healthcare system with no financial barrier to access to health services and cancer drugs. The objective of the study is to investigate associations between, on the one hand, incidence and survival of patie
Externí odkaz:
https://doaj.org/article/4c7565b0d1ce481980192cfea894b4bf